BeOne Medicines AG — Sponsor Intelligence | 33 EU Trials

Filter these 33 trials by condition, phase, country and more.

Open in Search →

33 Registered trials

21 Recruiting

12 Completed trials

16 Countries active

32 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase III: 11 Phase II/III: 2 Phase II: 4 Phase I/II: 5 Phase I: 10 Phase I (FiH): 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gastric cancer 4 Hormone receptor positive HER2 negative breast cancer 3 Mantle cell lymphoma 3 Marginal zone lymphoma 2 Ovarian cancer 2 Colorectal cancer 2 Mantle cell lymphoma refractory 2 Richter's syndrome 2 Endometrial cancer 2 Prostate cancer 2 Non-small cell lung cancer 2 Squamous cell carcinoma of head and neck 2

Top IMPs

ZANUBRUTINIB 12 N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE 11 VENETOCLAX 5 RITUXIMAB 4 TISLELIZUMAB 4 BGB-16673 3 OBINUTUZUMAB 3 BENDAMUSTINE HYDROCHLORIDE 2 LBL-007 2 ACALABRUTINIB 1 AZACITIDINE 1 BGB-15025 CITRATE 1

All trials

33 total

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 Phase III 9 countries ACALABRUTINIB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NIT…
A Study of Zanubrutinib Versus Tacrolimus in Participants With Primary Membranous Nephropathy (ALMOND) Recruiting

2022-501147-32-00 Phase II/III 4 countries ZANUBRUTINIB
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 Phase III 14 countries ZANUBRUTINIB
Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Recruiting

2023-508883-31-00 Phase III 3 countries OCIPERLIMAB; PAMIPARIB; TISLELIZUMAB
An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting

2024-511267-28-00 Phase III 9 countries ZANUBRUTINIB
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitu… Recruiting

2025-524857-15-00 Phase I 1 country
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033,… Recruiting

2025-524136-19-00 Phase I 2 countries
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, … Recruiting

2025-523553-34-00 Phase I 2 countries
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity … Recruiting

2025-523165-19-00 Phase I 1 country
The purpose of this study is to determine whether Tislelizumab, when given as a subcutaneous (SC) injection, reaches the same drug levels in… Recruiting

2025-522862-58-00 Phase III 6 countries TISLELIZUMAB
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Phase III 10 countries BGB-16673; PIRTOBRUTINIB
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Phase III 12 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Phase I/II 3 countries BGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEX…
A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Phase III 5 countries BENDAMUSTINE HYDROCHLORIDE; BGB-16673; IDELALISIB; RITUXIMAB; VENETOCLAX
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Patients Treated for Blood Cancers Recruiting

2024-518829-15-00 Phase I/II 1 country N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 Phase III 6 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 I… Recruiting

2024-515307-19-00 Phase I 3 countries
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting

2023-507751-30-00 Phase I/II 5 countries CARFILZOMIB; DARATUMUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AM…
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD… Recruiting

2023-506888-34-00 Phase I 1 country
A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting

2022-502157-33-00 Phase I (FiH) 5 countries
Study of BGB-11417 in Patients with Myeloid Malignancies Recruiting

2023-508881-14-00 Phase I/II 4 countries AZACITIDINE; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITRO…
A Phase 2 Study to Investigate Sonrotoclax combined with Zanubrutinib Versus Zanubrutinib alone in Patients With Previously Untreated Chroni… Ended

2024-513970-23-00 Phase II 3 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended

2023-506948-17-00 Phase III 9 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…
Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended

2023-503235-18-00 Phase II 4 countries N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SUL…

Showing 1–24 of 33 trials

← All sponsors A–Z